Startseite>>Signaling Pathways>> Tyrosine Kinase>> VEGFR>>ZK-261991

ZK-261991

Katalog-Nr.GC31816

ZK-261991 ist ein oral aktiver VEGFR-Tyrosinkinase-Inhibitor mit einer IC50 von 5 nM fÜr VEGFR2.

Products are for research use only. Not for human use. We do not sell to patients.

ZK-261991 Chemische Struktur

Cas No.: 886563-25-3

Größe Preis Lagerbestand Menge
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2.

ZK-261991 inhibits cellular receptor autophosphorylation in KDR-PAECs with an IC50 of 2 nM. ZK991 inhibits VEGFR-3 autophosphorylation concentration dependently with an IC50 of 20 nM[1].

ZK991 results in a significantly reduced recruitment of CD11b+ and LYVE-1+ cells into the murine cornea. ZK991 significantly improves the graft survival rate after corneal transplantation[1].

[1]. Deniz Hos, et al. Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation. Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1836-1842.

Bewertungen

Review for ZK-261991

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ZK-261991

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.